Rolf Stahel
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau J, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clin Res Rep 2022; 3:100430.
Nov 7, 2022Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
Nov 7, 2022JTO Clin Res Rep 2022; 3:100430
Sun Suna, Qi Weihong, Rehrauer Hubert, Ronner Manuel, Hariharan Ananya, Wipplinger Martin, Meiller Clément, Stahel Rolf, Früh Martin, Cerciello Ferdinando, Fonteneau Jean-François, Jean Didier, Felley-Bosco Emanuela
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer 2020; 147:30-38.
Jun 23, 2020Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Jun 23, 2020Lung Cancer 2020; 147:30-38
Gachechiladze Mariam, Soltermann Alex, Rulle Undine, Weder Walter, Stahel Rolf, Kolář Zdeněk, Shani Ilay, Hajduch Marian, Vbrková Jana, Vojta Petr, Smičková Petra, Kolek Vítězslav, Überall Ivo, Skanderová Daniela, Škarda Josef, Jörger Markus
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
Kresoja-Rakic J, Cerciello F, Früh M, Stahel R, Weder W, Lam W, Martinez V, Minatel B, Ronner M, Kirschner M, Szpechcinski A, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. Noncoding RNA 2019; 5
Jun 17, 2019miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
Jun 17, 2019Noncoding RNA 2019; 5
Kresoja-Rakic Jelena, Cerciello Ferdinando, Früh Martin, Stahel Rolf, Weder Walter, Lam Wan L, Martinez Victor D, Minatel Brenda, Ronner Manuel, Kirschner Michaela B, Szpechcinski Adam, Felley-Bosco Emanuela
Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. Eur J Cancer 2018; 96:64-72.
Apr 17, 2018Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Apr 17, 2018Eur J Cancer 2018; 96:64-72
Wolpert Fabian, Preusser Matthias, Kaufmann Philipp Antonio, Reyns Nicolas, Roth Patrick, Frauenfelder Thomas, Dummer Reinhard, Stahel Rolf, Stupp Roger, Neidert Marian Christoph, Regli Luca, Andratschke Nicolaus, Leske Henning, Petyt Gregory, Füreder Lisa Michaela, Rushing Elisabeth, Berghoff Anna Sophie, Weller Michael, Le Rhun Emilie
Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárková I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer 2017; 105:31-38.
Jan 18, 2017Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
Jan 18, 2017Lung Cancer 2017; 105:31-38
Gachechiladze Mariam, Soltermann Alex, Weder Walter, Stahel Rolf, Baty Florent, Kolář Zdeněk, Bouchal Jan, Langová Kateřina, Grygárková Ivona, Kolek Vítězslav, Škarda Josef, Jörger Markus
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Med Wkly 2013; 143:w13791.
May 7, 2013Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
May 7, 2013Swiss Med Wkly 2013; 143:w13791
Samaras Panagiotis, Renner Christoph, Stahel Rolf, Knuth Alexander, Taverna Christian, Schäfer Niklaus G, Mischo Axel, Schanz Urs, Siciliano Raffaele D, Honegger Hanspeter, Haile Sarah, Buset Elefteri M, Petrausch Ulf, Zardavas Dimitrios, Stenner-Liewen Frank
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
Nov 1, 2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Nov 1, 2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
Aug 9, 2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Aug 9, 2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
Feb 1, 2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Feb 1, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9.
May 1, 2003Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
May 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9
Betticher Daniel C, Stahel Rolf, Weder Walter, Stupp Roger, Egli Fritz, Furrer Markus, Honegger Hanspeter, Wernli Martin, Cerny Thomas, Spiliopoulos Anastase, Roth Arnaud D, Hsu Schmitz Shu-Fang, Tötsch Martin, Hansen Eva, Joss Christine, von Briel Christian, Schmid Ralph A, Pless Miklos, Habicht James, Ris Hans-Beat
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
D'Addario G, Ketterer N, Fey M, Cavalli F, Lohri A, Egli F, Stahel R, Maibach R, Torhorst J, Dieterle A, Cerny T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leukemia & lymphoma 2003; 44:133-8.
Jan 1, 2003HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
Jan 1, 2003Leukemia & lymphoma 2003; 44:133-8
D'Addario Giannicola, Ketterer Nicolas, Fey Martin, Cavalli Franco, Lohri Andreas, Egli Fritz, Stahel Rolf, Maibach Rudolf, Torhorst Joachim, Dieterle Alexander, Cerny Thomas